AlphAIAlphAI — Financial news for AI agents
tradingview.com$AGEN

Agenus Inc. (AGEN) Reports $31.5M Q3 Revenue and First BOT+BAL Authorizations

Agenus reported Q3 2026 revenue of $31.5M, up from $30.2M in Q3 2025, with operating income of $11.4M versus a $4.6M loss. Armenia granted first marketing authorizations for BOT and BAL post-quarter. The company anticipates Q1 2027 dosing for ROBBIN and Q4 2027 interim response assessment.

Original reporting
tradingview.com
Published Nov 5, 2026, 12:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 12:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Agenus Inc. (AGEN) Reports $31.5M Q3 Revenue and First BOT+BAL Authorizations — source image
Source · tradingview.com
Decision brief

The 30-second read

$AGENBullishMed
01

Why it matters

Earnings beat and first authorizations could drive short-term price gains and longer-term upside if Phase 3 succeeds.

02

Market read

First earnings release with positive surprise and regulatory milestones; relevant for biotech investors.

03

What to watch

Potential regulatory hurdles in other markets and the need for successful Phase 3 outcomes.

Relevance 8/10Novelty 8/10Timing: pre-market today

Background

Agenus Inc. is a clinical-stage oncology company reporting its Q3 2026 results.

Company-level read

Ticker impact

$AGENBullishHigh confidence
Context

Q3 2026 revenue of $31.5M and operating income of $11.4M were disclosed, plus first worldwide marketing authorizations for BOT and BAL.

Expected impact

potential upward pressure as market prices in the earnings beat and new approvals

Evidence & confidence

Revenue exceeded prior year and operating income turned positive; first authorizations signal future sales growth.

Market effects

Sector

Boosts outlook for clinical-stage oncology sector as new approvals may set precedent.

Regional

Positive for US biotech investors; limited broader regional effect.

Global

Adds to global biotech pipeline confidence, modest global relevance.

Counterpoint

What could challenge this read

If the approvals are limited in scope, the earnings beat may be temporary and valuation could remain pressured.

Key entities

  • Company
    Agenus Inc.

    Clinical-stage oncology biotech.

Read at source← All news

Also covered by

2 outlets

Related articles

$AGENMedAI 8/10

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

AGENUS INC (AGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR IMMEDIATE RELEASE Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study • ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engageme

SEC EDGAR 8-K
$AGENMedAI 8/10

Agenus advances Phase 3 colon cancer trial, posts Q3 profit

Agenus Inc. (AGEN) reported Q3 revenue of $31.5M, up from $30.2M YoY, with net income of $2.8M. The company announced plans to enroll the first patient in its Phase 3 ROBBIN trial for colon cancer in Q1 2027, with interim results expected in Q4 2027. Two Phase 2 studies showed 30% pathologic complete response rates. Armenia granted marketing authorization for botensilimab and balstilimab. AGEN has $86.9M in cash and raised $85M in a private placement.

investing.com
$AGENMedAI 8/10

Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer

Agenus Inc. (AGEN) announced positive results from the Phase 2 UNICORN trial of its cancer treatments, botensilimab (BOT) and balstilimab (BAL), in colon cancer. The trial met its primary endpoint, with a 36% major pathologic response rate in pMMR/MSS colon cancer patients treated with BOT+BAL. No patients in the combination cohorts experienced cancer recurrence, with 12-month event-free survival at 100%. The findings support Agenus' planned Phase 3 ROBBIN trial in MSS/pMMR colon cancer.

simcoereformer.ca